The company is a large company listed on the Shanghai Stock Exchange dedicated to providing high-quality products and services for human health. As one of the top 100 enterprises in China's pharmaceutical industry, the company focuses on the development direction of innovation and creativity, high quality, and high technology. Its business covers four major sectors: scientific research and development, pharmaceutical industry, traditional Chinese medicine industry, and financial investment. It is one of the most innovative pharmaceutical enterprises in China's pharmaceutical industry. The company's main business is pharmaceutical R&D, production and sales. Main products: 3 protected varieties of traditional Chinese medicine: Cuproton Capsules, Compound Qinlan Oral Liquid, and Pediatric Hot Quick Clear Syrup, as well as 4 exclusive varieties of Compound Qalan Oral Liquid, Lingqi Plus Oral Liquid, and Compound Baitouweng Capsules. The company won the “Leading Power · High-Quality Development of Chinese Medicine” Achievement Enterprise and Achievement Brand Award; it was also shortlisted on the Ministry of Industry and Information Technology's 2022 Green Manufacturing List and on the “National Green Factory List”. The list of China's top 100 pharmaceutical industry series, ranked 26th in the “2022 Chinese Traditional Chinese Medicine Companies”; ranked 21st in the “2022 TOP30 Listed Chinese Medicine Companies”, 22nd in the “2022 Top 100 Chinese Medicine Companies”, 23rd in the “2023 China Proprietary Chinese Medicine Industry TOP100”, 29th in the “2023 China Pharmaceutical R&D Strength Ranking”, and 48th in the “2022 Top 100 Chinese Pharmaceutical Manufacturing Companies”. With high quality development results and representative product - injectable hemostone, it won the title of “Excellent Brand Enterprise of Chinese Ethnic Medicine for the Year 2022 - 2023”.
No Data